Given the complexity of the immune network in RA, biological agents targeting immune cells and cytokines have emerged in an endless stream in recent years, among which infliximab targeting TNF-α and TCZ targeting IL-6R are the most widely used in clinical practice. The gene discussed is IL6R; the disease is rheumatoid arthritis.